Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190725 | 1.00 | ERN1 (0.58) | ERN1CYP1A2CYP3A4HSD17B10USP2 | |
| SCHEMBL25035627 | 0.90 | ERN1 (0.58) | ERN1CYP1A2CYP3A4HSD17B10USP2 | |
| SCHEMBL22190651 | 0.90 | ERN1 (0.58) | ERN1CYP1A2CYP3A4HSD17B10USP2 | |
| SCHEMBL29353080 | 0.90 | ERN1 (0.58) | ERN1CYP1A2CYP3A4HSD17B10USP2 | |
| SCHEMBL22190877 | 0.85 | ERN1 (0.56) | ERN1CYP1A2CYP3A4HSD17B10USP2 | |
| SCHEMBL29356032 | 0.85 | ERN1 (0.56) | ERN1CYP1A2CYP3A4HSD17B10USP2 | |
| SCHEMBL22190987 | 0.81 | ERN1 (0.49) | ERN1CYP1A2CYP3A4HSD17B10USP2 | |
| SCHEMBL29355891 | 0.81 | ERN1 (0.49) | ERN1CYP1A2CYP3A4HSD17B10USP2 | |
| SCHEMBL22191060 | 0.80 | ERN1 (0.67) | ERN1 | |
| SCHEMBL25035489 | 0.80 | ERN1 (0.70) | ERN1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |